- Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech
- The rapidly growing $130 billion coffee industry is at risk as global warming reduces the availability of viable land for coffee cultivation by up to 50% by 2050
- Compared to traditional methods of coffee production, Pluri’s cell-based coffee is estimated to reduce carbon footprint by slashing water usage by 98% and reducing growing areas by 95% (thus preventing deforestation)
FDA Casts Doubt on Merck/AstraZeneca’s Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC).
